Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026, press release concerning its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs but reaffirms the collaboration's goal of supporting Phase 3 recruitment for its HLP003 program in major depressive disorder and expanding outreach in veteran communities.
The company stated that the partnership aligns with a recent executive order aimed at advancing mental health treatments and clinical research participation. The HLP003 program, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder.
Helus Pharma is focused on developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. In addition to HLP003, the company is developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder, and has an extensive research portfolio of investigational NSAs.
The correction clarifies that while specific references to Veterans Exploring Treatment Solutions were removed, the partnership with TARA Mind remains focused on supporting veteran communities and clinical research. The full press release is available at https://ibn.fm/re8HL.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. For company updates, visit www.helus.com or follow on X, LinkedIn, YouTube, and Instagram.
This announcement is significant as it underscores the company's commitment to transparency and its strategic alignment with federal initiatives to improve mental health treatment access for veterans. The correction ensures accurate representation of the partnership's scope while maintaining focus on the Phase 3 trial recruitment and veteran outreach goals.
